Pfizer's Crizotinib Eases Past FDA With Targeted Population
Xalkori is the second targeted oncologic approved with a companion diagnostic this year, FDA says, following Roche's Zelboraf just 10 days prior.
Xalkori is the second targeted oncologic approved with a companion diagnostic this year, FDA says, following Roche's Zelboraf just 10 days prior.